Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Metacrine Inc (Metacrine) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for the treatment of patients with liver and gastrointestinal diseases. It develops its proprietary portfolio of non-bile acid FXR agonists through its chemistry and biology platform. The company's lead program includes MET409, a next-generation farnesoid X receptor (FXR) agonist intended for the treatment of non-alcoholic steatohepatitis, irritable bowel syndrome with diarrhea and inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. The company also develops a pipeline of drug candidates for the treatment of inflammation and fibrosis. Metacrine is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 373, 231 Market Pl, San Diego, California, 94583
Website
metacrine.com/
Telephone
1 858 2814948
Industry
Pharmaceuticals and Healthcare
Products and Services
| Products |
|---|
| MET409 |
Competitor Comparison
| Key Parameters | Metacrine Inc | Galectin Therapeutics Inc | G-Tech Medical Inc | NovaTarg Therapeutics Inc | TheracosBio LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | Norcross | Mountain View | Piedmont | Framingham |
| State/Province | California | Georgia | California | North Carolina | Massachusetts |
| No. of Employees | - | 15 | - | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Hogan | Director | Non Executive Board | - | - |
| Dave Maggio | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer